Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sage Therapeutics, Inc. - Common Stock (NQ: SAGE )

5.780 +0.350 (+6.45%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sage Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Delta Air Lines Posts Downbeat Earnings, Joins United Airlines, American Airlines And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
19 Analysts Have This To Say About Sage Therapeutics
Via Benzinga
Mama's Creations, GameStop And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Sage Therapeutics Reports Phase 2 Huntington's Data
On Tuesday before the market opened, Sage Therapeutics announced findings regarding Huntington's Disease (HD) based upon topline results from the Phase 2 SURVEYOR Study. 
Via Benzinga
Sage Therapeutics Announces Phase 2 SURVEYOR Study Reinforces Cognitive Impact of Huntington’s Disease
From Sage Therapeutics
Via Business Wire
Cracking The Code: Understanding Analyst Reviews For Sage Therapeutics
Via Benzinga
In-Depth Examination Of 9 Analyst Recommendations For Sage Therapeutics
Via Benzinga
Sage Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire
Wall Street's Top 10 Stock Calls This Week - Sunday, June 2
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the week of May 27 through June 2, 2024. 
Via Talk Markets
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month
Via Benzinga
Sage Therapeutics to Participate in Upcoming May Investor Conferences
From Sage Therapeutics
Via Business Wire
Demystifying Sage Therapeutics: Insights From 5 Analyst Reviews
Via Benzinga
Peeling Back The Layers: Exploring Sage Therapeutics Through Analyst Insights
Via Benzinga
SAGE Stock Earnings: Sage Therapeutics Misses EPS, Beats Revenue for Q1 2024
SAGE stock results show that Sage Therapeutics missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Hilton Worldwide Reports Upbeat Results, Joins Hasbro, Vertiv Holdings And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Netflix, ON Semiconductor And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Crude Oil Dips 3%; U.S. Bancorp Profit Tops Views
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 100 points on Wednesday. The Dow traded up 0.04% to 37,813.77 while the NASDAQ fell 0.78% to 15,742.21.... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Nasdaq Down Over 1%; Sage Therapeutics Shares Plunge
U.S. stocks traded lower midway through trading, with the Dow Jones index falling around 100 points on Wednesday. The Dow traded down 0.32% to 37,678.27 while the NASDAQ fell 1.16% to 15,681.95. The... 
Via Benzinga
Topics Stocks
Exposures US Equities
Neurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson's Data
Sage Therapeutics' Phase 2 study on dalzanemdor (SAGE-718) for mild cognitive impairment in Parkinson's Disease. Learn about topline results, safety, and future milestones in 2024. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings. 
Via Benzinga
Sage Stock Collapses To Record Low After Parkinson's Drug Misses Its Mark
Safe Therapeutics emphasized it's still testing the same drug in patients with Alzheimer's and Huntington's diseases. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
J B Hunt Transport Reports Downbeat Earnings, Joins ASML And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining over 100 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Present at Upcoming March Investor Conferences
From Sage Therapeutics, Inc.
Via Business Wire
These Analysts Boost Their Forecasts On Sage Therapeutics Following Q4 Results
Sage Therapeutics, Inc. (NASDAQ: SAGE) reported better-than-expected fourth-quarter revenue results on Wednesday. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.